TRAIL, Fas Ligand, TNF and TLR3 in Cancer /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
Cham :
Springer International Publishing : Imprint: Springer,
2017.
|
| Edición: | 1st ed. 2017. |
| Colección: | Resistance to Targeted Anti-Cancer Therapeutics,
12 |
| Materias: |
Tabla de Contenidos:
- Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer
- TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer
- IAPs and Resistance to Death Receptors in Cancer
- Bcl-2 Proteins and TRAIL Resistance in Melanoma
- Regulation of Caspase-Mediated Apoptosis by the Tumor Suppressor Par-4
- Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy
- Atypical Immune Functions of CD95/CD95L
- TLR3 is a Death Receptor Target in Cancer Therapy
- Fas/CD95, Lipid Rafts and Cancer
- Role of Sphingolipids in Death Receptor Signalling
- Post-Translational Modifications and Death Receptor Signalling
- System Modeling of Receptor-Induced Apoptosis.